The Role Of Risk Aversion In Reverse-Payment Agreements
Law360 (May 31, 2019, 2:57 PM EDT) -- A reverse-payment agreement arises when a brand-name drug manufacturer provides consideration to a generic drug company to settle its patent litigation in exchange for the generic drug company’s agreement not to enter the market until a certain date. Such agreements, and whether they are anti-competitive, continue to generate many legal disputes and debates among economists and legal scholars.
In its Federal Trade Commission v. Actavis Inc. decision, the U.S. Supreme Court ruled that reverse payment agreements should be analyzed under the rule of reason (i.e., one must assess the competitive effects of reverse payment through a careful economic analysis). One of...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!